The Wolverine Stack (BPC-157 + TB-500): Protocol, Dosing Chart, Before & After, Side Effects

Key takeaways

• The Wolverine stack is BPC-157 plus TB-500, two research peptides injected together for injury recovery and named after a comic-book character who heals instantly. It is a marketing bundle, not a medical protocol.
• Each component has animal data and almost nothing else: BPC-157 has about 220 rodent papers, mostly from one lab, and three small uncontrolled human pilot studies; TB-500 has one rat study and no human study at all, as FDA said in July 2026.
• The combination has never been tested in a human trial. The only data are 4 knee-pain patients in a 2021 phone survey and a 2026 study of 32 rats in which the stack was no better than either peptide alone.
• The dosing charts that circulate (BPC-157 250 to 500 mcg daily, TB-500 2 to 2.5 mg twice weekly) were written by sellers; no human study has used them, and the before-and-after posts that accompany them are testimonials for a product with unverified contents.
• As of October 2026 no US pharmacy may compound either component, so there is no legal version of the stack. A clinic offering it is selling research vials, and FDA's 2026 warning letters say a 'research use only' label does not make that lawful.

What the Wolverine stack is and where the name comes from

The Wolverine stack is two vials. One contains BPC-157, a synthetic 15-amino-acid fragment of a protein found in human gastric juice; the other contains what is sold as TB-500, usually a synthetic 7-amino-acid fragment of the protein thymosin beta-4. The two are reconstituted and injected under the skin, on a schedule copied from vendor forums, for weeks at a time, by people with tendon, ligament and muscle injuries, and increasingly by people with nothing wrong who want to 'recover faster'. Some sellers combine them in a single 'blend' vial.

The name is borrowed from the Marvel character whose mutant healing factor closes wounds in seconds. It was coined on bodybuilding and biohacking forums in the 2010s, where both peptides had arrived from the horse-racing and research-chemical trade, and it did its job: the phrase is searched tens of thousands of times a month. By July 2026 it had reached FDA's advisory committee, where supporters of TB-500 described it as part of 'the so-called wolverine stack' taken with BPC-157 (HPM 2026).

The stack has no inventor, no trial, no established dose and no legal supply. What follows is what each half has behind it, what the combination has (very little), and how to read the people selling it.

What is in the vials

BPC-157 was first described in 1993 by a pharmacology group in Zagreb and has since been the subject of roughly 220 papers, mostly from that group, in which it speeds healing of cut tendon, ligament, muscle and gut lining in rodents, largely by growing new blood vessels through the VEGFR2 pathway (Hsieh 2017). As a 2026 drug-development review notes, it has no validated formulation, no human pharmacokinetics and fewer than 30 human subjects in total, all in uncontrolled pilot studies (Mateescu 2026). Our BPC-157 profile grades every claim.

TB-500 is a product name, not a molecule name. Thymosin beta-4 is a 43-amino-acid protein present in nearly every cell; the fragment doping laboratories identified in TB-500 is the acetylated amino acids 17 to 23, Ac-LKKTETQ, the protein's actin-binding site and the part that promotes cell migration and angiogenesis (Esposito 2012). What is in a TB-500 vial varies: a 2023 laboratory analysis of products bought online found contents that were not consistently what the descriptions claimed (Delcourt 2023), and FDA told its advisory committee in 2026 that sequences and molecular weights vary by vendor. Our TB-500 profile separates the fragment from the protein.

Put together, then, the Wolverine stack is a rodent-proven peptide with no human trial plus a vendor-defined peptide with no human study, both bought from sellers no one inspects.

What each component has in evidence

The rat tendon study that anchors every BPC-157 sales page is worth describing once. Rats had the Achilles tendon cut 5 mm above the heel and received BPC-157 into the abdomen once a day from 30 minutes after surgery; over 14 days the treated tendons bore more load, the animals walked better and the gap filled with collagen faster than in saline-treated rats (Staresinic 2003). It is a clean experiment in young healthy animals with a fresh surgical cut, dosed immediately; the buyer of the Wolverine stack is a 40-year-old with a six-month-old partial tear, injecting an unverified vial into belly fat. As for the thymosin beta-4 trials that TB-500 sellers cite, the molecule in them was the 43-amino-acid protein given by eye drop, gel or intravenous line (Ruff 2010), not the seven-amino-acid fragment in the vial.

What has actually been tested of the combination

Here is the complete record, as of October 2026.

In animals: one study. In 2026 a Turkish orthopedic group randomized 32 rats with a transected and repaired Achilles tendon to four groups of eight: no treatment, BPC-157 at 10 mcg/kg a day, TB-500 at 60 mcg/kg a day, or both, injected into the abdomen for four weeks. TB-500 alone produced significantly higher load to failure and better tissue scores than controls; BPC-157 alone improved tissue scores without reaching significance; and the combination, in the authors' words, 'did not confer additional benefits compared to either agent alone' (Bicer 2026). The authors suggest the two may act on the same downstream pathways, which would make stacking them redundant rather than synergistic.

In humans: four people in a chart review. The 2021 retrospective study of intra-articular BPC-157 for knee pain at a Florida clinic included four patients who received BPC-157 with thymosin beta-4; three reported improvement when telephoned months later, with no validated outcome measure, no control group and no imaging (Lee 2021). That is every human datum on the combination. No clinical trial of the Wolverine stack, in any design, in any country, has been published or registered with results.

So the claim that the two peptides are 'synergistic', which appears on nearly every page selling them, has been tested exactly once, in rats, and was not supported.

The 'protocol' and the 'dosing chart'

The BPC-157 numbers are at least traceable: scaled from the rat dose by body weight or body surface area, a 70 kg adult lands between 110 and 700 mcg a day, and sellers chose the middle. That is a conversion, not a study, and says nothing about whether a subcutaneous shot reaches a tendon in a person. The TB-500 numbers cannot be traced to anything: scaled either way, the rat dose would be a daily injection of 1 to 4 mg, not a twice-weekly one, and the 'loading and maintenance' structure has been copied from forum to forum since the horse-racing days. The 'units' arithmetic is explained on our reconstitution page and in the calculator; knowing how to read a chart is not a reason to follow it.

'Before and after': what the genre is

The Wolverine stack's evidence base, in the sense of what persuades buyers, is testimonial: forum posts, short videos and clinic pages describing a hamstring that healed in three weeks or an elbow that stopped hurting. There is no study of the stack that measured anything in a group of people, and there never has been, so every 'result' you will see is a self-selected story about an unverified product.

Three facts explain why the stories are easy to generate. Most acute soft-tissue injuries improve over two to six weeks with rest and rehabilitation, and a peptide started at the same time gets the credit. The people who post are the ones who felt better; those who felt nothing, or got an abscess, rarely write it up. And nobody who posts a before-and-after knows what was in the vial, because no one tested it. A testimonial for the Wolverine stack is a testimonial for rest and time plus an unknown injectable. If the stack worked the way the stories say, the trial that would show it would cost a few hundred thousand dollars and would have been run by now by one of the companies selling millions of dollars of it.

The risks of combining two unstudied injectables

The risks of each peptide are covered in its own profile; stacking adds a layer.

1. Two angiogenesis promoters at once. BPC-157 grows blood vessels through VEGFR2 (Hsieh 2017). The TB-500 fragment is the migration-and-angiogenesis site of thymosin beta-4, a protein overexpressed in many cancers that, when overexpressed in mouse melanoma cells, roughly doubled tumor size and quadrupled lung metastases (Cha 2003). Nobody has studied either peptide in people with cancer, let alone both. FDA and several advisers raised the cancer signal for TB-500 in July 2026, and one committee member who voted no said he worried specifically about its use in combination with other peptides (Healio 2026).
2. Unknown interactions. The one study of the combination suggests the two may act on shared pathways. Whether that produces redundancy, amplification or something else in a person is unknown, because the question has never been asked in a person.
3. Two immunogenicity risks. Any injected peptide can provoke antibodies; impurities and aggregates in uncharacterized products make it more likely, and immunogenicity was one of FDA's stated concerns in its 2026 review. Two unregulated peptides mean two chances.
4. Two unverified products. TB-500 products have been shown to contain things other than what their labels say (Delcourt 2023); BPC-157 vials have no verified identity, potency or sterility either. Injection-site infection, abscess and, rarely, bloodstream infection are the predictable consequences of non-sterile injectables, and the stack doubles the injections.
5. Blood pressure and the vascular system. BPC-157 acts on nitric oxide signaling; thymosin beta-4 is involved in platelet biology. Neither has been studied in people with hypertension, heart disease or clotting disorders, and the combination has not been studied in anyone.
6. No one in the chain. No pharmacist checks the vial, no clinician with a license on the line sets the dose, and no adverse event reporting system receives the outcome. If something goes wrong, the seller's website is the only record, and the seller edits it.

The legal reality in October 2026

Neither half of the stack may be compounded by a licensed US pharmacy. Both were placed in FDA's Category 2, the bin for bulk substances that may present significant safety risks, between 2023 and 2024; both came off it on April 15, 2026 after their nominations were withdrawn; and on July 23, 2026 FDA's advisory committee voted 8 to 6 with one abstention to recommend each for the 503A bulks list, over the objection of FDA's reviewers, who recommended against all seven peptides reviewed that week and said TB-500 has no studies of its own (HPM 2026). A recommendation is advisory: FDA must propose, take comments on and finalize a rule before any pharmacy may use either substance, and as of our last check of the Federal Register on October 9, 2026, no proposed rule exists. The legal tracker carries the timeline.

In practice, then, there is no legal version of the Wolverine stack. The vials come from the research-chemical market, and in 2026 FDA addressed that market directly: warning letters in March and August told online peptide sellers that a 'research use only' label does not protect a product whose website provides dosing guidance, injection instructions, reconstitution calculators or bundled bacteriostatic water, because those show it is intended as a drug for human use (ArentFox Schiff 2026). The August letters concerned other peptides, but the reasoning applies word for word to pages selling Wolverine 'protocols' and 'dosing charts'. The letters go to sellers; possessing or injecting the peptides is not a crime. For athletes the picture is stricter: TB-500 is named on the WADA list under S2 and prohibited at all times, BPC-157 is prohibited under S0 (WADA 2026), and in September 2025 USADA announced a four-year sanction for a triathlete who possessed and used both and promoted them to his followers (USADA 2025).

How to read a 2026 clinic offering the stack

Clinics and telehealth sites that list the Wolverine stack in 2026 are, without exception, dispensing research-grade vials; the consultation and the prescription are a wrapper, since a prescription cannot make a non-compoundable substance compoundable. The tells:

• The pharmacy question has no answer. Ask which pharmacy will make it, in which state, and on what legal basis a 503A pharmacy may use BPC-157 or TB-500 in October 2026. A real pharmacy cannot answer, because there is none.
• 'FDA-approved for compounding.' FDA approves drugs, not compounding, and these two are not even on the list that permits compounding. The phrase is wrong twice.
• 'Recommended by FDA.' An advisory committee recommended them over FDA's objection. That is the opposite of FDA recommending them.
• A chart instead of a clinician. A dosing chart emailed after checkout, with units per injection and a cycle length, is the document FDA cited as evidence of drug marketing in its warning letters.
• A 'blend' vial. No study has used a combined product; a blend exists to simplify shipping and raise the price.
• Before-and-after galleries and 'client results'. See above.
• Bundles with prescribable peptides. Some clinics list the stack beside sermorelin, which licensed pharmacies can compound, or tesamorelin, an approved drug, so the legitimacy of one rubs off on the others. It does not.

A clinic that answers the pharmacy question honestly will tell you it cannot provide the stack. That clinic is worth talking to about what it can provide: for a tendon or ligament injury, a rehabilitation and loading program, analgesia, imaging, and the procedures or surgery the injury calls for, all of which have outcome data that neither peptide has.

If you are already injecting it

This page will not tell you how to use the Wolverine stack, because nobody knows how, and the only responsible instruction is to stop and see a clinician about the injury. If you are going to inject anyway, the one thing within your control is harm reduction around the injection itself, which our general guides cover: how to inject peptides explains sterile technique, needle length, site rotation, sharps disposal and the difference between a normal site reaction and an infection, and how to reconstitute peptides covers bacteriostatic water, storage and beyond-use dates. Those pages were written for pharmacy products with a label; a research vial has none, so the margin for error is smaller. Seek care the same day for spreading redness, warmth or pus at a site, fever, hives, facial swelling or wheezing, and tell any clinician you see that you are injecting these peptides; it changes how they read your symptoms.

Bottom line

The Wolverine stack is a name, a chart and a pair of vials. Behind the name is a comic book; behind the chart is a forum; behind the vials is a rodent literature for one peptide, a single rat study for the other, and no human trial of either by injection, let alone of both together. The one experiment that tested the combination found it no better than its parts. FDA's reviewers opposed both components in July 2026, no US pharmacy may compound either, and the sellers who supply them have been told by FDA that a research label does not make the trade legal. If you have an injury, the treatments with evidence are available on prescription. If you want the stack anyway, you are buying an experiment on yourself with no control group, no label and no one to call.

Frequently asked questions

+−What is the Wolverine peptide stack?

It is the marketing name for injecting BPC-157 and TB-500 together, usually subcutaneously, for injury recovery. The name comes from the Marvel character whose wounds heal instantly. BPC-157 is a 15-amino-acid fragment of a gut protein with extensive rat data and three small uncontrolled human studies; TB-500 is a 7-amino-acid fragment of thymosin beta-4 with one rat study and no human study. No clinical trial has ever tested the two together, in people or animals, beyond a single 2026 rat experiment in which the combination was no better than either peptide alone.

+−Does the Wolverine stack work? What do the before-and-after results show?

Nobody knows whether it works, because no controlled study of the stack exists and no outcome has ever been measured in a group of people taking it. 'Before and after' posts and testimonials are not evidence: most soft-tissue injuries improve over weeks with or without treatment, the people posting selected themselves, and the vials they used had no verified content. The one rat study of the combination found no benefit beyond the single agents.

+−What is the Wolverine stack dosage?

There is no studied dose of the stack in humans, or of TB-500 in humans at all. The charts that circulate, typically BPC-157 at 250 to 500 mcg once or twice daily and TB-500 at 2 to 2.5 mg twice a week for four to six weeks, then monthly, were written by sellers and copied between forums; none traces to a trial. The rodent doses were 10 mcg/kg of BPC-157 and 60 mcg/kg of TB-500 injected into the abdomen daily, which do not convert to any of the chart numbers.

+−What are the side effects of the Wolverine peptide stack?

No study has recorded them. People who inject research vials describe injection-site pain and lumps, headache, nausea, flushing, fatigue and dizziness. The theoretical risks are more serious: both peptides promote new blood vessel growth, and thymosin beta-4 drives cell migration and made mouse melanoma tumors larger and more metastatic; both can provoke immune reactions; the vials have no verified sterility or content; and nobody has studied the two together, so any interaction is unknown.

+−Are Wolverine stack capsules or oral versions real?

They exist for sale, which is not the same as working. BPC-157 is stable in stomach acid and worked in rat drinking water, but no human oral pharmacokinetic study has been published. TB-500 is a short peptide with no oral data in any species. An oral 'Wolverine' capsule is two unapproved drugs in one pill, with no evidence that either reaches a tendon.

+−Is the Wolverine stack legal in 2026? Can a doctor prescribe it?

Neither component may be compounded by a licensed US pharmacy as of October 2026: both came off FDA's Category 2 list in April 2026 and were recommended by FDA's advisory committee in July, but FDA has not published a rule, and FDA's own reviewers opposed both. A prescription cannot make them compoundable, so a clinic 'prescribing' the stack is dispensing research vials. Possessing them is not a crime; selling them for human use is, whatever the label says, as FDA's 2026 warning letters to peptide vendors made explicit.

+−Is the Wolverine stack banned in sports?

Yes. TB-500 is named on the 2026 WADA Prohibited List under S2 (thymosin-beta 4 and its derivatives, e.g. TB-500), prohibited at all times. BPC-157 is prohibited under S0, the category for substances not approved for human use. In September 2025 USADA announced a four-year sanction for a triathlete who possessed and used both and promoted them on social media. Detection methods exist for both peptides and their metabolites.

+−What peptides should not be stacked together?

The honest answer is that no stack of research peptides has been studied, so there is no evidence-based list of safe or unsafe combinations. The combinations to be most wary of are two or more injectables with overlapping mechanisms (two angiogenesis promoters, two growth hormone secretagogues), anything stacked with growth hormone or insulin, and any stack in a person with a cancer history. A clinician managing a single prescribable peptide with monitoring is a different proposition from a vendor's bundle.

+−How long does the Wolverine stack take to work?

No study has measured a timeline in people. Seller pages promise results in two to four weeks, which is also roughly how long most muscle strains and mild tendon injuries take to improve on their own with rest and rehabilitation, which is why testimonials are so easy to generate. In the rat studies the peptides were started 30 minutes after a surgical cut and assessed over two to twelve weeks; that tells you nothing about a months-old human injury.

Sources

1. StudyStaresinic M et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res 2003;21:976-83. (2003)
2. StudyHsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl) 2017;95:323-33. (2017)
3. StudyLee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med 2021;27(4):8-13. (2021)
4. ReviewMateescu DM et al. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics 2026;18:625. (2026)
5. StudyEsposito S et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal 2012;4:733-8. (2012)
6. StudyDelcourt V et al. TB500/TB1000 and SGF1000: a scientific approach for a better understanding of misbranded and adulterated drugs. Drug Test Anal 2023;15:458-64. (2023)
7. StudyRuff D, Crockford D, Girardi G, Zhang Y. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci 2010;1194:223-9. (2010)
8. StudyCha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst 2003;95:1674-80. (2003)
9. StudyBicer O et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg 2026;37:822-37. (2026)
10. NewsPalmer KL, Snow CD, Bass M. PCAC approves four bulk drug substances for the 503A list (BPC-157, KPV, TB-500, MOTS-c). FDA Law Blog, Hyman Phelps & McNamara, July 24, 2026. (2026)
11. NewsBascom E. FDA committee recommends looser restrictions for several peptides. Healio Endocrine Today, July 24, 2026. (2026)
12. NewsUS Anti-Doping Agency. Triathlon athlete Anthony McCauley accepts sanction for anti-doping rule violations (possession and use of BPC-157 and TB-500; promotion of prohibited peptides). September 17, 2025. (2025)
13. RegulatoryWorld Anti-Doping Agency. The 2026 Prohibited List (in force January 1, 2026): S2.3 growth factors and growth factor modulators names thymosin-beta 4 and its derivatives, e.g. TB-500; S0 covers non-approved substances. (2026)
14. NewsArentFox Schiff. RUO-ined: five peptide vendors learn that research use only is not a legal strategy (FDA warning letters of August 24, 2026). September 18, 2026. (2026)